**Supplementary Table 2.** 68 gene panel (ctDNA),comprising amplifications in 16 genes as well as some fusions and indels. Only non-synonymous alterations were analyzed (N = 400 patients).

|  |
| --- |
|  **POINT MUTATIONS AMPLIFICATIONS FUSIONS INDELS** |
| *AKT1* | *ALK* | ***APC*** | ***AR*** | *AR* | *ALK* | *EGFR* exon 19 deletions |
| *AFAR* | ***ARID1A*** | *ATM* | ***BRAF*** | *BRAF* | *RET* | *EGFR* exon 20 insertions |
| ***BRCA1*** | ***BRCA2*** | ***CCDN1*** | ***CCDN2*** | *CCNE1* | *ROS1* |  |
| ***CCNE1*** | *CDH1* | ***CDK4*** | ***CDK6*** | *CDK4* | *NTRK1* |  |
| ***CDKN2A*** | ***CDKN2B*** | *CTNNB1* | ***EGFR*** | *CDK6* |  |  |
| ***ERBB2*** | *ESR1* | *EZH2* | *FBXW7* | *EGFR* |  |  |
| ***FGFR1*** | ***FGFR2*** | *FGFR3* | *GATA3* | *ERBB2* |  |  |
| *GNA11* | *GNAQ* | *GNAS* | *HNF1A* | *FGFR1* |  |  |
| ***HRAS*** | *IDH1* | *IDH2* | *JAK2* | *FGFR2* |  |  |
| *JAK3* | ***KIT*** | ***KRAS*** | *MAP2K1* | *KIT* |  |  |
| *MAP2K2* | ***MET*** | *MLH1* | *MPL* | *KRAS* |  |  |
| ***MYC*** | ***NF1*** | *NFE2L2* | *NOTCH1* | *MET* |  |  |
| *NPM1* | ***NRAS*** | *NTRK1* | ***PDGFRA*** | *MYC* |  |  |
| ***PIK3CA*** | ***PTEN*** | *PTPN11* | ***RAF1*** | *PDGFRA* |  |  |
| *RET* | *RHEB* | *RHOA* | *RIT1* | *PIK3CA* |  |  |
| *ROS1* | *SMAD4* | *SMO* | *SRC* | *RAF1* |  |  |
| *STK11* | *TERT* | ***TP53*** | *VHL* | \*Complete exon coverage for genes in **bold** |